Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers

Clinical Therapeutics
Jinah JungHyeong-Seok Lim

Abstract

Avanafil is a selective phosphodiesterase type 5 inhibitor being developed for the treatment of erectile dysfunction. This study was conducted to meet Korean regulatory requirements for the marketing of avanafil. To this end, tolerability and pharmacokinetic properties of single and multiple oral doses of avanafil in healthy Korean male volunteers were assessed. A double-blind, randomized, placebo-controlled, parallel-group, dose-escalation study was conducted at the Asan Medical Center (Seoul, Korea). Subjects were randomized to receive either drug or placebo in blocks according to each dose. Subjects were randomly allocated to receive 50-, 100-, or 200-mg tablets of avanafil or placebo once daily for 7 days (avanafil:placebo, 8:2 in each dose group). Tolerability was assessed by monitoring vital signs and results of laboratory tests, 12-lead ECGs, and color discrimination tests. Blood samples of approximately 6 mL were collected in heparinized tubes before and 0.1, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after drug administration on days 1 and 7. Plasma concentrations of avanafil were measured using LC-MS/MS. Pharmacokinetic parameters of avanafil on days 1 and 7 were determined by noncompartmental analysis a...Continue Reading

References

Jul 7, 1993·JAMA : the Journal of the American Medical Association
Apr 29, 1999·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·D K WalkerP A Wright
Nov 5, 2002·Urology·Harin Padma-nathanFrancesco Montorsi
Nov 19, 2003·Current Urology Reports·Sharron H Francis, Jackie D Corbin
Apr 15, 2005·International Journal of Impotence Research·A OchiaiT Miki
Aug 3, 2005·Drugs·Konstantinos Hatzimouratidis, Dimitrios G Hatzichristou
Nov 18, 2005·The Urologic Clinics of North America·Puneet MassonRidwan Shabsigh
Sep 22, 2006·International Journal of Impotence Research·N MehrotraB Meibohm
Feb 20, 2007·Current Topics in Medicinal Chemistry·Michael J PalmerDavid G Brown
Feb 4, 2010·Developmental Science·Anna FranklinAlex White

❮ Previous
Next ❯

Citations

Apr 30, 2013·Bioorganic & Medicinal Chemistry·Hong X DingChristopher J O'Donnell
Feb 2, 2013·Therapeutic Advances in Urology·George T KediaKnut Albrecht
Nov 17, 2011·Drug Design, Development and Therapy·Amjad AlwaalSerge Carrier
Sep 14, 2012·Vascular Health and Risk Management·Ryan M Burke, Jeffery D Evans
Apr 20, 2014·International Journal of Endocrinology·Pietro GareriPasquale De Fazio
Jul 10, 2012·Expert Opinion on Drug Metabolism & Toxicology·Mohammad Amin RezvanfarMohammad Abdollahi
Apr 8, 2014·Current Medical Research and Opinion·Hongtao WangDahai Hu
May 18, 2016·Nature Reviews. Disease Primers·Faysal A YafiWayne J G Hellstrom
Jun 1, 2013·Journal of Pharmaceutical and Biomedical Analysis·Dhavalkumar Narendrabhai PatelHwee-Ling Koh
Aug 14, 2013·The Journal of Sexual Medicine·Zhen WangJingshan Shen
May 31, 2011·The Urologic Clinics of North America·Erin R McNamara, Craig F Donatucci
Jul 23, 2013·International Journal of Clinical Practice·W B SmithW J Hellstrom
Nov 9, 2010·Biochimica Et Biophysica Acta·Annamaria MorelliLuciano Adorini
Jul 16, 2016·Expert Review of Clinical Pharmacology·Jonathan L ZurawinWayne J G Hellstrom
Nov 22, 2013·The Annals of Pharmacotherapy·Jeffrey A KyleJerame K Hill
Aug 15, 2018·Expert Opinion on Pharmacotherapy·Ahmed I El-Sakka
Jul 26, 2019·Medical Mycology·M R DavisG R Thompson
Feb 2, 2020·International Journal of Impotence Research·Eylem Güven
Jul 1, 2013·Journal of Clinical Urology·Jas Kalsi, Asif Muneer
Feb 12, 2019·F1000Research·Sarah C KrzastekJason R Kovac
Dec 5, 2020·Expert Opinion on Pharmacotherapy·Ahmed M BakrAhmed I El-Sakka
Feb 18, 2021·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Elena BastiaFrancesco Impagnatiello
Jun 21, 2021·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Camilla Regina de Souza MadeiraRoberto Pontarolo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.